Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Medicare Self-Injectable Guidelines Maintain Split Within Drug Classes

Executive Summary

The Centers for Medicare & Medicaid Services' self-injectables guidelines would still divide Medicare coverage within a therapeutic drug class based on route of administration

You may also be interested in...



Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B

Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B

Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B

Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B

Oral Cancer Drugs, MS Self-Injectables Covered In Medicare Pilot Program

The Medicare conference agreement sets aside $200 mil. to pay for oral cancer therapies under a demonstration project

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel